1. Pink Sheet

EU Supplementary Protection Certificate Mechanism Needs To Go, Say Campaigners

 
• By Vibha Sharma

A group of more than 30 NGOs has urged the European Commission to consider abolishing the system of granting supplementary protection certificates to pharmaceutical companies, saying it delays generic competition and affects the availability of affordable medicines. A UK-based patent attorney, however, says the assertions made by the NGOs are not supported by the evidence.

Brain
SPCs prolong monopolies of originator pharmaceutical companies, say campaigners • Source: Shutterstock

Thirty-three civil society organizations have written an open letter to the European Commission urging it to abolish the current mechanism of awarding drug companies supplementary protection certificates (SPC). They claim that it "expands and extends" existing monopoly rights of pharmaceutical corporations, and results in higher medicines prices by preventing generic competition.

But patent attorney and SPC expert Mike Snodin dismissed the assertions regarding the alleged negative effects of SPCs on the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.